Does BRUKER CORPORATION have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores BRUKER CORPORATION (BRKR) 55.9 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 80, returns on capital 84, balance-sheet safety 0, capital discipline 34.

Is BRKR stock trading below its intrinsic value?

Against a deliberately conservative owner-earnings model (9% discount rate, 0% assumed growth, capped at 4%), estimated intrinsic value is $20.24 per share versus a recent price of $58.23 — 188% above value. This is an educational estimate computed from primary SEC filings, not investment advice.

How has BRKR's Moat Score changed over time?

The record logs 3 readings since Jul 17, 2026; the latest reads 55.9 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

BRUKER CORPORATION

BRKR · Healthcare · $8.9B mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power80

Median gross margin 47.8% over 10y, very stable.

Returns on capital84

Median ROIC 18.0%, above the 9% hurdle in 80% of years.

Balance-sheet safety0

Net debt/EBITDA 5.4x, interest coverage 1x.

Capital discipline34

Owner earnings -3.8%/yr, share count shrinking (buybacks).

Margin of safety

Above valueOn sale

188% above value

Owner earnings (normalized): $277.1M
Est. intrinsic value / share: $20.24
Recent price: $58.23
Discount to value: 188% above value

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

18 years of fundamentals

The business, in plain English

BRUKER CORPORATION booked $3.4B of revenue in FY2025 in the Healthcare sector and kept 45.9% of it as gross profit — a solid-margin business by that measure. After every other cost, −0.3% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $1.1B (FY2009) to $3.4B (FY2025) — about 7.3% a year compounded over 16 years.

It earned 1.1% on invested capital in FY2025, with a median of 16.5% across 17 filed years. The Returns on Capital filter above scores it 84/100.

The balance sheet carried $1.9B of total debt in FY2025 against $120.9M of owner earnings — roughly 15.5 years of owner earnings to retire it all. Balance-Sheet Safety scores it 0/100.

The share count fell 7.9% between FY2010 and FY2025 — management has been retiring shares, which concentrates each remaining owner's claim. Capital Discipline scores it 34/100.

Put together: Returns on Capital is the strongest of the four filters (84/100) and Balance-Sheet Safety the weakest (0/100), which is how BRKR lands at 56/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

RevenueSales, as filed$3.4B FY2025

Gross marginRevenue kept after cost of goods45.9% FY2025

Return on invested capitalOperating profit on the capital employed1.1% FY2025

Owner earningsCash an owner could take out$120.9M FY2025

Gaps in a line mean that item isn’t in BRKR’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale55.9 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — BRKR has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#93 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#91ACAD ACADIA PHARMACEUTICALS INC56.2 out of 100, Shallow moatShallow moat
#92TDY TELEDYNE TECHNOLOGIES INC55.9 out of 100, Shallow moatShallow moat
#94HIMS HIMS & HERS HEALTH, INC.55.8 out of 100, Shallow moatShallow moat
#95PLX PROTALIX BIOTHERAPEUTICS, INC.55.7 out of 100, Shallow moatShallow moat

Compare BRKR with its nearest peers →All Healthcare companies on the Index →

Common questions about BRKR

Does BRUKER CORPORATION have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores BRUKER CORPORATION (BRKR) 55.9 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 80, returns on capital 84, balance-sheet safety 0, capital discipline 34.
Is BRKR stock trading below its intrinsic value?: Against a deliberately conservative owner-earnings model (9% discount rate, 0% assumed growth, capped at 4%), estimated intrinsic value is $20.24 per share versus a recent price of $58.23 — 188% above value. This is an educational estimate computed from primary SEC filings, not investment advice.
How has BRKR's Moat Score changed over time?: The record logs 3 readings since Jul 17, 2026; the latest reads 55.9 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows BRKR’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/BRKR"
  width="340" height="150" style="border:0"
  title="BRKR Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell BRKR. See the disclaimer.